Uncategorized

  • FDA grants global Medical Device company Biomimetic Innovations ‘Breakthrough Device’ designation for OsStic® Synthetic Injectable Structural Bio-Adhesive Bone Void Filler. 

    , , ,

    Shannon, Ireland, 19th January, 2024: Biomimetic Innovations Ltd today announced that OsStic® has been granted ‘Breakthrough Device’ designation by the FDA. The proposed indication statement for this novel new technology is; ” OsStic®Synthetic Injectable Bone Void Filler is a structural, mechanically enhanced bioadhesive for reduction, provisional fixation, or void filling of peri-articular fractures or defects…

    Read More...

  • 2024: A Transformative Year Ahead for PBC Biomed

    Driven by our dedicated team as well as our valued industry and academic partners, 2024 is set to become a transformative year for our commercialisation and developmental programmes. We would like to take this opportunity to thank our current partners and friends for your continued support and encouragement – we look forward to sharing further…

    Read More...

  • Strengthening the Bond Part III at OTA 2023

    Thank you to our panel of surgeon experts for another great ‘Strengthening the Bond’ symposium at the Orthopaedic Trauma Association conference last week. They also supported us with product demonstrations at our stand for any attendees interested in learning more about one of most exciting technologies – OsStic. Pictured is Dr Tracey Watson using OsStic with a…

    Read More...

  • Successful OCP Workshop at Bioceramics33

    PBC Biomed CSO Gerard Insley is pictured in action during the dedicated #OCP Workshop at the Bioceramics 33 event in Solothurn, Switzerland on October 17th. The purpose of this workshop was to create a forum for the world’s leading experts and industrial representatives to share their latest advances in OCP R&D. Well done to the extended panel of experts who…

    Read More...